Boston Children’s Hospital spin-out Mightier has scored an additional $250,000 for its emotional regulation video game program. The new investment was made by Modern Time Group. 

This additional funding comes on the heels on a $6.6 million Series A investment announced in May, which all together brings the company’s total money pot to roughly $10.35 million. 

WHAT THEY DO 

The company was created with the goal of helping kids regulate their emotions. Its program includes 25 bioresponsive mobile games and a special heart rate monitoring band. The games are aimed at help children learn coping skills like deep breathing and visualization. 

Parents also have access to a portal, which connects them with a clinical child’s development coach. The company business model is based on a monthly subscription. There is a one-time fee of $99, and then a monthly payment that ranges from $19 to $35 a month based on the service. 

WHAT IT’S FOR 

The new money and partnership with MTG will go towards adding more tools for users. 

“MTG works with some of the best game developers in the world,” Craig Lund, cofounder and CEO of Mightier, said in a statement. "This partnership is a great opportunity to work with top developers to add more games to the Mightier platform to keep kids engaged and learning.”

MARKET SNAPSHOT

Biofeedback-based video games designed to improve children’s health have cropped up in a few different areas over the years.

A 2017 clinical trial showed that a biofeedback game had potential in treating ADHD. In the game, from developer NeuroPlus, children wear an EEG monitor and additional sensors that measure movement and muscle tension. The readings from those sensors actually control the game — in one game, the player rides a dragon that speeds up the more they focus and slows down when their attention wanders. 

Akili Interactive Labs, well known as one of the leading digital therapeutics companies, is also focusing on ADHD via a game for kids called Project: Evo — although it currently has no biofeedback component. The company has been actively pursuing FDA clearance of Project: Evo for roughly a year now, and has a fair body of clinical evidence backing its case. In addition, 2018 saw the the company bring in $68 million in new funding, which brought its total backing to just over $140 million.